Early IL-6 Levels Predict Sepsis-Induced Coagulopathy with High Specificity

Anticipating the Coagulopathic Cascade in Septic Shock

Sepsis remains a primary driver of critical illness and mortality in the United States, characterized by a dysregulated host response to infection that frequently leads to multi-organ failure [1]. A central feature of this pathology is the systemic activation of inflammatory and coagulation pathways, often manifesting as sepsis-induced coagulopathy, a precursor to the more lethal disseminated intravascular coagulation [2]. While early goal-directed resuscitation and prompt antibiotic administration remain the cornerstones of management, identifying which patients will progress to severe hematologic dysfunction remains a significant clinical challenge [3]. Interleukin-6 has long been recognized as a key mediator in this inflammatory cascade, serving as a biomarker for both neonatal sepsis and the cytokine storms observed in severe viral infections [4, 5]. A new study investigates whether specific thresholds of this cytokine can predict the onset of overt coagulopathy before standard clinical scores manifest.

Quantifying the Risk of Immunothrombosis

The progression to disseminated intravascular coagulation marks a lethal inflection point in sepsis, driving mortality rates to between 40% and 80%. Central to this clinical deterioration is interleukin-6, a pleiotropic cytokine that promotes leukocyte activation and immunothrombosis (the formation of microvascular blood clots driven by an overactive immune response). By fueling these procoagulant pathways, interleukin-6 serves as a functional mediator of the widespread thrombosis that ultimately causes ischemic end-organ failure. Identifying patients at risk for this hematologic collapse before it becomes clinically apparent is essential for improving survival outcomes in the intensive care unit. To quantify this risk, researchers conducted a single-center observational analysis of 105 adult sepsis patients admitted to an intensive care unit between October 2022 and July 2024. On hospital Day 1, serum interleukin-6 levels were measured using an electrochemiluminescence immunoassay (a highly sensitive laboratory technique that uses electrochemical reactions to emit light for precise protein quantification). The researchers then monitored these patients over a three-day period to diagnose disseminated intravascular coagulation based on the Japanese Association for Acute Medicine (JAAM) criteria, a validated scoring system that incorporates platelet counts, systemic inflammatory response syndrome scores, and global coagulation markers. This longitudinal approach allowed the team to correlate early cytokine elevations with the subsequent development of overt coagulopathy.

Defining the 5,571 pg/mL Threshold

Within the study cohort, disseminated intravascular coagulation developed in 75 patients (71.4%). When comparing the inflammatory profiles of these individuals to those who did not develop the condition, the researchers observed a distinct elevation in early cytokine levels. Specifically, log-transformed interleukin-6 concentrations (a statistical adjustment used to normalize highly variable biological data) were significantly higher in patients who developed the condition compared to those who did not (3.70±0.86 versus 3.00±0.82, p=0.001). The relationship between early cytokine levels and the severity of coagulopathy became more pronounced as the clinical course progressed, with correlations between log interleukin-6 and JAAM scores strengthening from Day 1 (p=0.03) to Day 3 (p=0.0006). To determine a clinically actionable threshold, the team utilized receiver operating characteristic analysis, a statistical method that plots true-positive against false-positive rates to determine the optimal diagnostic cutoff. This analysis identified an optimal cutoff of log interleukin-6 3.746, which corresponds to an absolute interleukin-6 concentration of 5,571 pg/mL. At this specific threshold, the biomarker demonstrated high utility for ruling in the complication, yielding 88.9% specificity and 58.8% sensitivity for predicting disseminated intravascular coagulation, with an area under the curve of 0.715. For the practicing intensivist, this high specificity means a value above 5,571 pg/mL serves as a strong warning signal, flagging a subset of septic patients who require aggressive monitoring before standard coagulation panels deteriorate.

Predictive Value Before Overt Coagulopathy

The true clinical utility of the 5,571 pg/mL threshold lies in its ability to forecast hematologic collapse before overt diagnostic criteria are met. In this study, among 46 patients exceeding the 5,571 pg/mL threshold, 89.1% developed disseminated intravascular coagulation by Day 3. More importantly for early clinical intervention, the biomarker served as a leading indicator for those who appeared hematologically stable at admission. Of the patients who exceeded the interleukin-6 threshold but did not initially meet diagnostic criteria for disseminated intravascular coagulation, 75% subsequently developed the condition. These findings suggest that early cytokine elevation precedes the clinical manifestation of coagulopathy, providing a critical window for reassessment before overt organ failure occurs. To ensure these findings were not confounded by other variables, the researchers performed multivariable logistic regression, a statistical model that adjusts for factors such as age, comorbidities, and infection site. This analysis confirmed that log interleukin-6 is a strong independent predictor of disseminated intravascular coagulation (odds ratio [OR] 2.430, 95% confidence interval [CI] 1.327 to 4.449, p=0.004). Additionally, the Sequential Organ Failure Assessment (SOFA) score, a standard intensive care metric tracking multi-system organ dysfunction, also independently predicted the condition (OR 1.224, 95% CI 1.066 to 1.407, p=0.004). While both metrics are valuable for risk stratification, the higher odds ratio associated with interleukin-6 levels highlights its specific strength in signaling the onset of sepsis-induced coagulopathy.

Synergy with Clinical Severity Scores

While interleukin-6 is a potent standalone biomarker, its predictive power peaks when integrated with established clinical severity metrics. The researchers evaluated the diagnostic accuracy of combining cytokine levels with the Sequential Organ Failure Assessment (SOFA) score, which aggregates dysfunction across the respiratory, cardiovascular, hepatic, coagulation, renal, and neurological systems. This combined interleukin-6 and SOFA logistic regression model achieved an area under the curve of 0.773 (95% CI 0.684 to 0.861), a statistical measure where 1.0 represents perfect prediction. This integrated approach demonstrated improved discriminatory performance compared to log interleukin-6 alone, which yielded an area under the curve of 0.715, proving that the biomarker and clinical severity scores provide complementary data regarding the patient's physiological state. The clinical value of this dual-metric model is most pronounced in its ability to rule out false positives, ensuring that intensive interventions are directed toward the most appropriate patients. At an optimal threshold of 0.810, the combined interleukin-6 and SOFA model demonstrated 100% specificity for predicting the development of disseminated intravascular coagulation. For physicians managing septic shock, a Day 1 interleukin-6 concentration exceeding 5,571 pg/mL, especially when viewed alongside a high SOFA score, provides a definitive early warning signal. By identifying high-risk patients before the onset of irreversible microvascular thrombosis, this predictive framework offers a specific window to initiate targeted interventions and potentially mitigate the high mortality rates associated with septic coagulopathy.

References

1. Martin GS, Mannino DM, Eaton S, Moss M. The Epidemiology of Sepsis in the United States from 1979 through 2000. New England Journal of Medicine. 2003. doi:10.1056/nejmoa022139

2. Yang C, Zhu J, Zhang Y, et al. Effects of transcutaneous auricular vagus nerve stimulation on sepsis-induced coagulopathy: protocol for a randomised controlled trial.. BMJ open. 2025. doi:10.1136/bmjopen-2025-102904

3. Dellinger RP, Levy MM, Carlet J, et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Medicine. 2007. doi:10.1007/s00134-007-0934-2

4. Alansari AN, Zaazouee MS, Elshanbary AA, Mani S, Messaoud M. Diagnostic accuracy of interleukin-6 (IL-6) as a significant biomarker in late-onset neonatal sepsis: an updated systematic review and meta-analysis.. European journal of pediatrics. 2025. doi:10.1007/s00431-025-06409-w

5. Wang Y, Zhu K, Dai R, et al. Specific Interleukin-1 Inhibitors, Specific Interleukin-6 Inhibitors, and GM-CSF Blockades for COVID-19 (at the Edge of Sepsis): A Systematic Review.. Frontiers in pharmacology. 2021. doi:10.3389/fphar.2021.804250